药物洗脱球囊在冠脉介入治疗后支架内再狭窄病变中的应用进展

经皮冠状动脉介入治疗(PCI)技术日趋成熟,已经在很大程度上提高了冠心病患者的生存率及生存质量。近10余年来,随着药物洗脱支架(DES)的普遍应用,介入治疗进入了新的阶段。然而,支架内再狭窄(ISR)的处理仍然是治疗的难点。药物洗脱球囊(DEB)能够将抗增生药物输送至靶病变部位,同时由于避免植入支架,减少了植入物刺激血管壁引起的炎症反应及内膜过度增生,从而降低了再狭窄率。因此,DEB在ISR等特殊病变治疗中具有特殊的优势。

Application progresses of drug-eluting balloon in treating in-stent restenosis after percutaneous coronary intervention

With the technological progress of percutaneous coronary intervention (PCI), suvival rate and the quality of life have been improved in patients with coronary heart disease, moreover, PCI has entered a new development stage with the wide application of drug eluting stents (DES) in the last decade. Nevertheless, in-stent restenosis disease is still tough to deal with. Drug-eluting balloon (DEB) can deliver the antiproliferative drug to the target lesions without stent implantation, so as to reduce the restenosis rate by inhibition of inflammation reaction and intima hyperplasy induced by implants. Therefore, DEB has special advantages in PCI of in-stent restenosis.